{"id":"c1-esterase-inhibitor-human-liquid","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis / thromboembolic events"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypersensitivity / anaphylaxis"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:14:03.822636","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"C1 esterase inhibitor (C1-INH) is a serine protease inhibitor that regulates the initial steps of the intrinsic coagulation pathway, fibrinolytic system, and complement cascade. In hereditary angioedema (HAE) and acquired angioedema (AAE), deficiency or dysfunction of C1-INH leads to uncontrolled activation of these cascades, resulting in excessive bradykinin production and angioedema. Replacement with human C1-INH restores normal regulation and prevents or treats acute angioedema attacks.","oneSentence":"C1 esterase inhibitor replaces or augments the deficient or dysfunctional C1 inhibitor protein, which normally suppresses excessive activation of the contact system and complement cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:36.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis"},{"name":"Acquired angioedema (AAE) — acute attack treatment"}]},"_fixedFields":["pubmed(27)"],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"recentPublications":[{"date":"2025 Feb","pmid":"39583036","title":"Omics analysis reveals galectin-3 to be a potential key regulator of allergic inflammation in hereditary angioedema.","journal":"The journal of allergy and clinical immunology. Global"},{"date":"2023 Nov","pmid":"38006386","title":"Application of a dried blood spot based proteomic and genetic assay for diagnosing hereditary angioedema.","journal":"Clinical and translational allergy"},{"date":"2021 Sep 28","pmid":"34583739","title":"HAE patient self-sampling for biomarker establishment.","journal":"Orphanet journal of rare diseases"},{"date":"2021","pmid":"34234594","title":"Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis.","journal":"Nature and science of sleep"},{"date":"2021 Feb 20","pmid":"33388640","title":"A robust multiplexed assay to quantify C1-inhibitor, C1q, and C4 proteins for in vitro diagnosis of hereditary angioedema from dried blood spot.","journal":"Journal of pharmaceutical and biomedical analysis"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"C1 esterase inhibitor [human] liquid","genericName":"C1 esterase inhibitor [human] liquid","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"C1 esterase inhibitor replaces or augments the deficient or dysfunctional C1 inhibitor protein, which normally suppresses excessive activation of the contact system and complement cascade. Used for Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis, Acquired angioedema (AAE) — acute attack treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}